Pharmaceutical

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).

Jun 1, 2025 - 06:00
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

Astellas and Evopoint sign ADC licensing deal

Next Article

FDA Halts Rocket Pharmaceuticals’ Gene Therapy Trial After Patient Death

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Cancer drug shortages should have patients rioting in the streets

Opinion: Cancer drug shortages should have patients rio...

Jun 20, 2023

Rentschler closes UK cell and gene therapy facility and does a pivot to biologics 

Rentschler closes UK cell and gene therapy facility and...

Feb 1, 2025

FDA accepts resubmission of Ardelyx’s NDA for XPHOZAH

FDA accepts resubmission of Ardelyx’s NDA for XPHOZAH

May 18, 2023